|
Name |
(-)-alpha-Himachalene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(4aS,9aR)-3,5,5-trimethyl-9-methylidene-2,4a,6,7,8,9a-hexahydro-1H-benzo[7]annulene
|
|
SMILES |
CC1=C[C@H]2[C@@H](CC1)C(=C)CCCC2(C)C
|
|
InChI |
InChI=1S/C15H24/c1-11-7-8-13-12(2)6-5-9-15(3,4)14(13)10-11/h10,13-14H,2,5-9H2,1,3-4H3/t13-,14-/m0/s1
|
|
InChIKey |
ZJSIKVDEOWWVEH-KBPBESRZSA-N
|
|
Synonyms |
(-)-alpha-Himachalene; alpha-Himachalene; 3853-83-6; 1DB5J66V5P; CHEBI:49218; (-)-2,7(14)-himachaladiene; 1H-Benzocycloheptene, 2,4a,5,6,7,8,9,9a-octahydro-3,5,5-trimethyl-9-methylene-, (4aS,9ar)-; .alpha.-Himachalene; (4aS,9aR)-3,5,5-trimethyl-9-methylidene-2,4a,6,7,8,9a-hexahydro-1H-benzo[7]annulene; alpha-cis-Himachalene; 1H-Benzocycloheptene, 2,4a,5,6,7,8,9,9a-octahydro-3,5,5-trimethyl-9-methylene-, (4aS-cis)-; alpha-Himachalene, (-)-; UNII-1DB5J66V5P; himachal-4,11-diene; (1R,6S)-alpha-himachalene; .ALPHA.-CIS-HIMACHALENE; CHEMBL3120652; DTXSID30191859; (-)-.ALPHA.-HIMACHALENE; .ALPHA.-HIMACHALENE, (-)-; LMPR0103480001; Q27121538; (4aS,9aR)-3,5,5-trimethyl-9-methylene-2,4a,5,6,7,8,9,9a-octahydro-1H-benzo[7]annulene; (4aS,9aR)-3,5,5-trimethyl-9-methylidene-2,4a,5,6,7,8,9,9a-octahydro-1H-benzo[7]annulene
|
|
CAS | 3853-83-6 | |
PubChem CID | 11830551 | |
ChEMBL ID | CHEMBL3120652 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.5 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.478 |
Caco-2 Permeability: | -4.587 | MDCK Permeability: | 0.00001370 |
Pgp-inhibitor: | 0.875 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.882 |
30% Bioavailability (F30%): | 0.117 |
Blood-Brain-Barrier Penetration (BBB): | 0.045 | Plasma Protein Binding (PPB): | 93.77% |
Volume Distribution (VD): | 2.475 | Fu: | 5.21% |
CYP1A2-inhibitor: | 0.552 | CYP1A2-substrate: | 0.722 |
CYP2C19-inhibitor: | 0.42 | CYP2C19-substrate: | 0.906 |
CYP2C9-inhibitor: | 0.459 | CYP2C9-substrate: | 0.845 |
CYP2D6-inhibitor: | 0.032 | CYP2D6-substrate: | 0.734 |
CYP3A4-inhibitor: | 0.275 | CYP3A4-substrate: | 0.311 |
Clearance (CL): | 3.735 | Half-life (T1/2): | 0.157 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.338 |
Drug-inuced Liver Injury (DILI): | 0.213 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.116 |
Skin Sensitization: | 0.077 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.327 | Eye Irritation: | 0.935 |
Respiratory Toxicity: | 0.054 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001316 | 0.577 | D0F2AK | 0.256 | ||||
ENC001663 | 0.519 | D04ATM | 0.250 | ||||
ENC001565 | 0.519 | D0A2AJ | 0.247 | ||||
ENC001563 | 0.519 | D0Z1XD | 0.244 | ||||
ENC001826 | 0.519 | D0D2VS | 0.244 | ||||
ENC001630 | 0.519 | D02KIU | 0.241 | ||||
ENC000800 | 0.464 | D00YWP | 0.241 | ||||
ENC002227 | 0.464 | D04GJN | 0.239 | ||||
ENC002652 | 0.439 | D0V2JK | 0.237 | ||||
ENC000588 | 0.390 | D0P1FO | 0.235 |